A multicenter, open-label, randomized study comparing the efficacy of atorvastatin versus usual care in reducing refractory hypercholesterolemia in high-risk patients to target levels

Current Therapeutic Research - Clinical and Experimental

Volumn 61, Issue 4, 2000, Pages 175-190

  Habib, Gilbert ^a   Paillard, François ^b   Charpentier, Guillaume ^d   Angellier, Jean François ^d   Roux, Thierry ^c   Portal, Jean Jacques ^c   Maigret, Pascal ^c  

^a TIMONE HOSPITAL   (France)

^b PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^c Parke Davis Europe   (France)

^d CHU Marseille ^*

Author keywords

Atorvastatin; Hypercholesterolemia; Lipid lowering therapy; Low density lipoprotein cholesterol

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; BEZAFIBRATE; CERIVASTATIN; CIPROFIBRATE; CREATINE KINASE; FENOFIBRATE; FLUINDOSTATIN; GEMFIBROZIL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; ENZYME BLOOD LEVEL; FEMALE; GASTROINTESTINAL SYMPTOM; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MYALGIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0034106943     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(00)89032-3     Document Type: Article

References (36)

1. 1. Sans S, Kesteloot H, Kromhout D, et al. Task Force Report. The burden of cardiovascular disease mortality in Europe. Eur Heart J. 1997;18:1231-1248.
2. 2. Pyörälä K, De Backer G, Graham I, et al. Prevention of coronary heart disease in clinical practice. Eur Heart J. 1994;15:1300-1331.
3. 3. Sempos CT, Cleeman JI, Caroll MD, et al. Prevalence of high blood cholesterol among US adults. JAMA. 1993;269:3009-3014.
4. 4. Sheperd J. A call to action. Eur Heart J. 1998;19(Suppl M):M2-M7.
5. 5. Wood D, DeBacker G, Faergman O, et al. Prevention of coronary heart disease in clinical practice. Eur Heart J. 1998;19:1434-1503.
6. 6. Smith SC, Blair S, Criqui MH, et al. Preventing heart attack and death in patients with coronary disease. American Heart Association medical/scientific statement. Circulation. 1995;92:2-4.
7. 7. ASPIRE Steering Group. A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action of Secondary Prevention through Intervention to Reduce Events). Principal results. Heart. 1996;75:334-342.
8. 8. EUROASPIRE Study Group. EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: Principal results. Eur Heart J. 1997;18: 1569-1582.
9. 9. Pearson TA, Laurora I, Chu H, Kafoneck S. The Lipid Treatment Assessment Project (L-TAP). Arch Intern Med. 2000;160:459-467.
10. 10. Faergeman O. Challenges to best practice: Why are guidelines not implemented? Eur Heart J. 1999;1(Suppl J):J12-J17.
11. 11. Ellrodt AG, Conner L, Riedinger M, et al. Measuring and improving physician compliance with clinical practice guidelines. Ann Intern Med. 1995;122:277-282.
12. 12. Wood D. European and American recommendations for coronary heart disease prevention. Eur Heart J. 1998;19(Suppl A):A12-A19.
13. 13. Prevention of coronary heart disease: Scientific background and new clinical guidelines. Recommendations of the European Atherosclerosis Society prepared by the International Task Force for the Prevention of Coronary Heart Disease. Nutr Metab Cardiovasc Dis. 1992;2:113-156.
14. 14. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;269:3015-3023.
15. 15. Schectman G, Hiatt J. Drug therapy for hypercholesterolemia in patients with cardiovascular disease: Factors limiting achievement of lipid goals. Am J Med. 1996;100:197-204.
16. 16. Marcelino JJ, Feingold KR. Inadequate treatment with HMG-CoA reductase inhibitor by health care providers. Am J Med. 1996;100:605-610.
17. 17. Lindholm LH, Ekbom T, Dash C, et al, on behalf of the CELL Study. The impact of health care advice given in primary care on cardiovascular risk. Br Med J. 1995;310:1105-1109.
18. 18. Les hypolipémiants. Le Concours Medical. 1996;41:58-72.
19. 19. Davidson M, McKinney J, Stein E, et al, for the Atorvastatin Study Group I. Comparison of the one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Am J Cardiol. 1997;79:1475-1481.
20. 20. Bertolini S, Bittolo Bon G, Cambell LM, et al. Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia. Atherosclerosis. 1997;130: 191-197.
21. 21. Dart A, Jerums G, Nicholson G, et al. A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. Am J Cardiol. 1997;80:39-44.
22. 22. Jones P, Kafonek S, Laurora I, Hunninghake D, for the CURVES Investigators. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia (The CURVES Study). Am J Cardiol. 1998;81:582-587.
23. 23. Illingworth DR. HMG-CoA reductase inhibitors. Curr Opin Lipidology. 1991;2:24-30.
24. 24. Illingworth DR, Tobert JA. A review of clinical trials comparing HMG-CoA reductase inhibitors. Clin Ther. 1994;16:366-385.
25. 25. Weir MR, Berger ML, Weeks ML, et al, for the Quality of Life Multicenter Group. Comparison of the effects on quality of life and the efficacy and tolerability of lovastatin versus pravastatin. Am J Cardiol. 1996;77:475-479.
26. 26. The Simvastatin Pravastatin Study Group. Comparison of the efficacy, safety and tolerability of simvastatin and pravastatin for hypercholesterolemia. Am J Cardiol. 1993;71: 1408-1414.
27. 27. Simvastatin Pravastatin European Study Group. Comparative efficacy and tolerability of 5 and 10 mg simvastatin and 10 mg pravastatin in moderate primary hypercholesterolemia. Cardiology. 1994;85:244-254.
28. 28. Douste-Blazy P, Ribeiro VG, Seed M, and the European Study Group. Comparative study of the efficacy and tolerability of simvastatin and pravastatin in patients with primary hypercholesterolemia. Drug Invest. 1993;6:353-361.
29. 29. Illingworth DR, Stein EA, Knopp RH, et al. A randomized multicenter trial comparing the efficacy of simvastatin and fluvastatin. J Cardiovasc Pharmacol Ther. 1996;1:23-30.
30. 30. Berger ML, Wilson HM, Liss CL. A comparison of the tolerability and efficacy of lovastatin 20 mg and fluvastatin 20 mg in the treatment of primary hypercholesterolemia. J Cardiovasc Pharmacol Ther. 1996;1:101-106.
31. 31. Jacotot B, Benghozi R, Pfister P, Holmes D, on behalf of the French Fluvastatin Study Group. Comparison of fluvastatin versus pravastatin treatment of primary hypercholesterolemia. Am J Cardiol. 1995;76:54A-56A.
32. 32. Schult K, Beil S. Efficacy and tolerability of fluvastatin and simvastatin in hypercholesterolemic patients. Clin Drug Invest. 1996;12:119-126.
33. 33. Lintott CJ, Sutherland WHF, Scott RS, Bremer J. Treating hypercholesterolemia with HMG-CoA reductase inhibitors: A direct comparison of simvastatin and pravastatin. Aust New Zealand J Med. 1993;23:381-386.
34. 34. Nawrocki JW, Weiss SR, Davidson MH, et al. Reduction of LDL-cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol. 1995;15:678-682.
35. 35. Cilla DD, Whitfied LR, Gibson DM, et al. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects. Clin Pharmacol Ther. 1996;60:687-695.
36. 36. Black DM, Bakker-Arkema RG, Nawrocki JW. An overview of the clinical safety profile of atorvastatin (lipitor), a new HMG-CoA reductase inhibitor. Arch Intern Med. 1998; 158:577-584.